08:00 , Dec 8, 2014 |  BC Week In Review  |  Clinical News

AVX-470 regulatory update

FDA granted Orphan Drug designation to AVX-470 from Avaxia to treat pediatric ulcerative colitis (UC). The oral inhibitor of tumor necrosis factor (TNF) alpha completed a Phase Ib trial in adults with UC (see BioCentury,...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

Enumeral Biomedical management update

Enumeral Biomedical Holdings Inc. (OTCQB:ENUM), Cambridge, Mass.   Business: Cancer   Hired: Kevin Sarney as VP of finance and chief accounting officer, formerly VP of finance and administration at Avaxia Biologics Inc.  ...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Clinical News

AVX-470: Phase Ib data

A double-blind, placebo-controlled, international Phase Ib trial in 36 patients with active UC showed that once-daily 0.2, 1.6 and 3.5 g doses of oral AVX-470 for 28 days were well tolerated with no treatment-related serious...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Company News

Avaxia Biologics board of directors update

Avaxia Biologics Inc. , Lexington, Mass.   Business: Antibodies, Endocrine/Metabolic, Autoimmune   Appointed: David Donabedian, managing director at AbbVie Biotech Ventures Inc.  ...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Financial News

Avaxia Biologics financial update

Avaxia raised $5 million in a final close of a series B round, bringing the total raised to $11.4 million. Existing investors Cherrystone Angels and Golden Seeds co-led the round. New investors AbbVie Inc. ;...
08:00 , Mar 4, 2013 |  BC Week In Review  |  Clinical News

AVX-470: Phase Ib started

Avaxia began a double-blind, placebo-controlled, international Phase Ib trial to evaluate 0.2, 1.6 and 3.5 g oral AVX-470 daily for 28 days in about 24 patients with active UC. Avaxia Biologics Inc. , Lexington, Mass....
08:00 , Jan 14, 2013 |  BC Week In Review  |  Financial News

Avaxia Biologics financial update

Avaxia paid $459,362 to the Massachusetts Life Sciences Center to repay a $375,000 loan from the lender issued in 2010. Avaxia Biologics Inc. , Lexington, Mass.   Business: Antibodies, Endocrine/Metabolic, Autoimmune   Date announced: 1/4/13...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Financial News

Avaxia Biologics completes venture financing

Avaxia Biologics Inc. , Lexington, Mass.   Business: Antibodies, Endocrine/Metabolic, Autoimmune   Date completed: 12/18/12   Type: Venture financing   Raised: $6.4 million   Investors: Cherrystone Angels; Golden Seeds; Beacon Angels; Boston Harbor Angels; Launchpad...
08:00 , Mar 5, 2012 |  BC Week In Review  |  Company News

Avaxia Biologics, Courtagen Life Sciences deal

The companies partnered to develop an assay to evaluate the effect of Avaxia's AVX-470 in treating gastrointestinal damage following radiation exposure in preclinical models and in humans. The companies will use Courtagen's Avantra Q400 Protein...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Company News

Avaxia Biologics board of directors update

Avaxia Biologics Inc. , Lexington, Mass.   Business: Antibodies, Endocrine/Metabolic, Autoimmune   Appointed: Henry Kay, active member of Boston Harbor Angels and Launchpad Venture Group  ...